Table 2.
Patterns of Prescription According to Combinations Used and Drug Type and Presence/Absence of Contraindications
| Pillars | Patients (n=305) |
|---|---|
| ACEi/ARB/ARNi+β‐blocker | 123 (40.3) |
| β‐Blocker | 64 (21.0) |
| ACEi/ARB/ARNi+MRA+β‐blocker | 61 (20.0) |
| β‐Blocker+MRA | 23 (7.5) |
| ACEi/ARB/ARNi | 9 (3.0) |
| ACEi/ARB/ARNi+MRA+β‐blocker+SGLT2i | 8 (2.6) |
| ACEi/ARB/ARNi+β‐blocker+SGLT2i | 4 (1.3) |
| MRA | 3 (1.0) |
| ACEi/ARB/ARNi+MRA | 3 (1.0) |
| β‐Blocker+MRA+SGLT2i | 1 (0.3) |
| β‐Blocker+SGLT2i | 1 (0.3) |
| SGLT2i | 0 (0.0) |
| No pillar | 5 (1.7) |
Data are given as number (percentage). ACEi indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNi, angiotensin receptor–neprilysin inhibitor; MRA, mineralocorticoid receptor antagonist; and SGLT2i, sodium‐glucose cotransporter 2 inhibitor.